Blue­print Med­i­cines po­ten­tial­ly de­lays Ay­vak­it de­ci­sion; Con­trol beats treat­ment in mesothe­lioma tri­al

→ Blue­print Med­i­cines filed an amend­ment to its ap­pli­ca­tion to get the gas­troin­testi­nal stro­mal tu­mor (GIST) drug Ay­vak­it ap­proved in fourth-line GIST, the com­pa­ny dis­closed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER